Table 1.
General characteristics of normal glucose participants and newly diagnosed T2DM patients.
| Variables | NDM | T2DM | P value |
|---|---|---|---|
| Gender (male/N) | 31/58 (53.4%) | 38/73 (52.1%) | 0.874 |
| Age (years) | 39.43 ± 12.08 | 41.03 ± 9.74 | 0.404 |
| BMI (kg/m2) | 26.80 ± 4.26 | 27.66 ± 3.39 | 0.204 |
| WHR | 0.91 ± 0.07 | 0.93 ± 0.06 | 0.100 |
| Betatrophin (pg/mL) | 407.41 (172.76–528.32) | 747.12 (544.26–1074.96) | <0.001∗ |
| Fasting glucose (mM) | 5.51 ± 0.63 | 12.11 ± 3.89 | <0.001∗ |
| Fast insulin (mIU/L) | 10.42 ± 5.83 | 15.10 ± 8.18 | <0.001∗ |
| C peptide (μg/L) | 1.65 ± 0.76 | 2.58 ± 2.97 | 0.021∗ |
| HOMA-IR | 2.88 ± 1.98 | 7.90 ± 3.89 | <0.001∗ |
| HOMA-%β | 92.45 ± 46.83 | 44.77 ± 37.37 | <0.001∗ |
| QUICKI | 0.34 ± 0.04 | 0.29 ± 0.02 | <0.001∗ |
| TC (mM) | 4.89 ± 1.23 | 5.47 ± 1.15 | 0.007∗ |
| TG (mM) | 1.29 (0.71–2.06) | 1.66 (1.09–2.35) | 0.213 |
| LDL-C (mM) | 3.32 ± 0.92 | 3.42 ± 0.95 | 0.559 |
| HDL-C (mM) | 1.50 ± 0.47 | 1.01 ± 0.37 | <0.001∗ |
| Uric acid (μmol/L) | 378.32 ± 110.26 | 335.40 ± 93.81 | 0.018∗ |
| ALT (IU/L) | 21 (14–37.8) | 21 (14.5–31) | 0.308 |
| AST (IU/L) | 24.28 ± 9.18 | 20.99 ± 12.48 | 0.096 |
BMI: body mass index; WHR: waist-to-hip ratio; FINS: fasting blood insulin; FBG: fasting blood glucose; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-%β: homeostasis model assessment of β cell function; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; QUICKI: Quantitative Insulin Sensitivity Check Index; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
∗ P < 0.05.